Heart valves top the list for recall-weary Feigal
This article was originally published in Clinica
The US FDA continues to complain about the high recall rate for medical devices. "Recalls are a problem. It's [a problem that is] old and it's getting older," David Feigal, director of the Center for Devices and Radiological Health, said at this week's annual meeting of the Regulatory Affairs Professionals Society, in Washington, DC.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.